Purpose: Aqueous suppressants (AS) are commonly used after glaucoma drainage device (GDD) surgery to limit early rises in intraocular pressure...
July 20, 2026
Tube exposure after glaucoma drainage device surgery is multifactorial; younger age is an established risk factor, while chronic ocular...
July 20, 2026
Purpose: To determine whether spatial decomposition of longitudinal retinal nerve fiber layer (RNFL) change maps reveals distinct modes of...
July 20, 2026
Effectiveness of laser trabeculoplasty Repeat treatment: If the first complete treatment is effective but the target pressure is not achieved or if...
July 20, 2026
Life-long follow-up of IOP is mandatory to avoid undetected progression. Orthoptic follow-ups as well as refractive correction are necessary to...
July 20, 2026
Purpose: To investigate retinomic changes preceding glaucoma onset and explore their predictive value. Design: A population-based, prospective...
June 24, 2026
Purpose: To elucidate associations between optic nerve head (ONH) structures and the retinal nerve fiber layer optical texture analysis...
June 24, 2026
Age-standardised prevalence of blindness and vision impairment [due to glaucoma] has decreased over the last 20 years in Europe. Although this is...
June 24, 2026
The appropriate use of antimetabolites is key to the success of bleb-forming devices (MIBS). Although higher doses of Mitomycin C result in better...
June 24, 2026
OCT angiography (OCTA) has gained great interest in glaucoma diagnosis (1, 2) and follow up(3). However, several conditions and diseases can impact...
June 24, 2026
Objectives: Progressive visual field (VF) loss from glaucoma affects patients’ quality of life (QoL). While treatments aim to preserve vision, the...
June 24, 2026
Congenital glaucoma occurs in about 1 in 12-18,000 births among white Europeans. Incidence can be 5 to 10 times higher if consanguinity of parents...
May 21, 2026
Raised intraocular pressure (IOP) and secondary glaucoma due to underlying uveitis is a well-acknowledged phenomenon (1). The clinician should...
May 21, 2026
Abstract: Glaucoma is a leading cause of irreversible blindness, primarily due to elevated intraocular pressure (IOP) that damages the retina and...
May 21, 2026
The only proven method of preserving visual function is to reduce the intraocular pressure (IOP). EGS Guidelines, 6th Edition, Page 159 Pearls...
May 21, 2026
Purpose: To evaluate the proportion of patients with, and anatomic predictors of, persistent angle closure 5 years after laser peripheral iridotomy...
May 21, 2026
Therapeutic options to reduce OSD include preservative-free or BAC-free medication, decreasing the number of eye drops (e.g., by using fixed...
April 22, 2026
Indications: Angle closure disease: high risk Primary Angle Closure Suspect, Primary Angle Closure [and] Primary Angle Closure Glaucoma; treatment...
April 22, 2026
Purpose: Miniaturized injectable delivery system (MIDS) devices engineered for zero-order release of timolol maleate are evaluated for intracameral...
April 20, 2026
Background: Glaucoma is a leading cause of blindness and is often undiagnosed. Owing to novel artificial intelligence (AI) technology,...
April 20, 2026
Pseudoexfoliation (PEX) is a common disorder and the most common cause of secondary glaucoma. Despite this, not all subjects with PEX will develop...
April 20, 2026
Background: Glaucoma is the leading cause of irreversible blindness globally, and the second leading cause of blindness in high-income countries....
March 22, 2026
Many european colleagues have engaged those around them to raise awareness about glaucoma during the World Glaucoma Week 2026. Here are some of the...
March 22, 2026
Professor Carlo Traverso has been awarded the 2026 Manfred Bootz Prize, a prestigious recognition dedicated to individuals who have made...
March 19, 2026
We are delighted to announce that Prof. Dr. Augusto Azuara-Blanco has received the AGS International Scholar Award from the American Glaucoma...
March 19, 2026